Beyond Cognition: Managing Alzheimer’s as an Integrated Neur

Overview
This series of brief episodes examines Alzheimer’s disease (AD) as an integrated neurodegenerative and neuropsychiatric syndrome. Drs. Marwan Sabbagh and Dani Cabral highlight challenges in clinical phenotyping and the consequences of treating neuropsychiatric symptoms (NPS) as separate comorbidities. The faculty also review emerging therapeutic approaches, including tau-targeting therapy for Alzheimer’s disease, as well as novel treatments for agitation and related NPS.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.
Commercial Support
This activity is supported by an independent educational grant from Bristol-Myers Squibb.
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires faculty and all individuals who can influence content to disclose any real or apparent financial relationships related to this activity. GLC has implemented processes to identify and mitigate potential conflicts of interest, ensuring independence, objectivity, balance, and scientific rigor prior to the activity.

The following faculty and planners have disclosed any relevant financial relationships with ineligible companies within the past 24 months

Faculty:
Marwan Noel Sabbagh MD, FAAN, FANA
Moreno Family Chair for Alzheimer’s Research
Department of Neurology
Barrow Neurological Institute
Phoenix, AZ

Stock Ownership: Alzheon, Athira, Lighthouse Pharmaceuticals, NeuroReserve, Optimal Cognitive Health Company, Reservoir Neuroscience, Seq BioMarque, TransDermix, uMethod Health, Versanum
Consulting Fees: AbbVie, Anavex, Cognito Therapeutics, Eisai, Johnson & Johnson, NeuroTherapia, Novo Nordisk, Inc., Signant, Synaptogenix
Speaker’s Bureau: Eisai, Lilly
Board of Director: EIP Pharma/CervoMed

Dani Cabral, MD
Founder and Medical Director, BrainLove
Assistant Professor, Departments of Neurology & Psychiatry
University of Arizona College of Medicine
Phoenix, AZ

Consulting Fees: Alpha Cognition, Eli Lilly, Lantheus

Reviewers/Content Planners/Authors:
Sandra Hannaford has no relevant relationships to disclose.
Rosanne Strauss, PharmD, has no relevant relationships to disclose.
Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Link AD pathology to cognition, behavioral symptoms, and NPS.
- Describe multi-pathway AD biology and how emerging therapies may translate clinically.
- Use an NPS neurocircuit framework to phenotype agitation and psychosis and align treatment decisions with evidence and safety.
Target Audience
This activity has been designed to meet the educational needs of Neurologists and Psychiatrists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare professionals involved in managing patients with Alzheimer’s Disease.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 
Global Learning Collaborative designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative designates this activity for 0.75 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative designates this activity for 0.75 contact hour(s)/ 0.75 CEUs) CEUs of pharmacy contact hour(s).
The Universal Activity Number for this program is JA0006235-0000-26-045-H01-P. This learning activity is competence-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credit(s). Approval is valid until April 28, 2027. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
System Requirements
- Supported Browsers (2 most recent versions):
- - Google Chrome for Windows, Mac OS, iOS, and Android
  - Apple Safari for Mac OS and iOS
  - Mozilla Firefox for Windows, Mac OS, iOS, and Android
  - Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 04/28/2026
Expiration Date: 04/28/2027